Current Gastroenterology Reports

, Volume 6, Issue 6, pp 506–513 | Cite as

Management of extraintestinal manifestations and other complications of inflammatory bowel disease

  • Edward V. LoftusJr
Article

Abstract

The past 18 months have seen many studies of the prevalence, pathogenesis, and treatment of the extraintestinal manifestations of inflammatory bowel disease (IBD). Inhibitors of tumor necrosis factor alpha have shown effectiveness in randomized trials for the treatment of spondyloarthropathies and ocular manifestations. Open-label studies suggest that these agents may be effective for pyoderma gangrenosum as well. The epidemiology of primary sclerosing cholangitis (PSC), and its relationship to IBD, is becoming clearer. Colorectal neoplasia in PSC remains an important clinical problem. Osteoporosis occurs more commonly in IBD, but the relative importance of corticosteroid use versus underlying chronic bowel inflammation as risk factors remains controversial. Chromoendoscopy may be an important means to improve detection of colorectal neoplasia in IBD. Observational studies suggest that prolonged use of aminosalicylates is associated with decreased risk of neoplasia, but data are conflicting. A randomized trial of ursodeoxycholic acid in PSC showed decreased risk of colorectal neoplasia in patients receiving the drug relative to those on placebo.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Orchard TR, Chua CN, Ahmad T, et al.: Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002, 123:714–718.PubMedCrossRefGoogle Scholar
  2. 2.
    Ricart E, Panaccione R, Loftus EV, et al.: Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004, 10:207–14. Comparison of the prevalence of EIMs and autoimmune diseases among sporadic IBD and familial IBD patients and their relatives.PubMedCrossRefGoogle Scholar
  3. 3.
    Manguso F, Sanges M, Staiano T, et al.: Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. Am J Gastroenterol 2004, 99:327–334. Cigarette smoking and appendectomy may increase the risk of certain EIMs in patients with IBD.PubMedCrossRefGoogle Scholar
  4. 4.
    Salvarani C, Vlachonikolis IG, van der Heijde DM, et al., and theEuropean Collaborative for IBDSG: Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 2001, 36:1307–1313.PubMedCrossRefGoogle Scholar
  5. 5.
    Bernstein CN, Blanchard JF, Rawsthorne P, Yu N: The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001, 96:1116–1122.PubMedCrossRefGoogle Scholar
  6. 6.
    Palm O, Moum B, Ongre A, Gran JT: Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002, 29:511–515.PubMedGoogle Scholar
  7. 7.
    Steer S, Jones H, Hibbert J, et al.: Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 2003, 30:518–522.PubMedGoogle Scholar
  8. 8.
    Mielants H, Veys E, Cuvelier C, De Vos M: HLA B27 related arthritis and bowel inflammation. II. Ileocolonoscopy and bowel histology in patients with HLA B27 related arthritis. J Rheumatol 1985, 12:294–298.PubMedGoogle Scholar
  9. 9.
    De Vos M, Mielants H, Cuvelier C, et al.: Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996, 110:1696–1703.PubMedCrossRefGoogle Scholar
  10. 10.
    Bjarnason I, Helgason KO, Geirsson AJ, et al.: Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 2003, 125:1598–1605.PubMedCrossRefGoogle Scholar
  11. 11.
    Hoffman IE, Demetter P, Peeters M, et al.: Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis 2003, 62:455–459.PubMedCrossRefGoogle Scholar
  12. 12.
    Miceli-Richard C, Zouali H, Lesage S, et al.: CARD15/NOD2 analyses in spondylarthropathy. Arthritis Rheum 2002, 46:1405–1406.PubMedCrossRefGoogle Scholar
  13. 13.
    Ferreiros-Vidal I, Amarelo J, Barros F, et al.: Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn’s disease. J Rheumatol 2003, 30:102–104.PubMedGoogle Scholar
  14. 14.
    van der Paardt M, Crusius JB, de Koning MH, et al.: CARD15 gene mutations are not associated with ankylosing spondylitis. Genes Immun 2003, 4:77–78.PubMedCrossRefGoogle Scholar
  15. 15.
    De Vos M, Laukens D, Marichal D, et al.: CARD15 mutations in patients with spondyloarthropathy are linked with disease progression and evolution to Crohn’s disease [abstract]. Gastroenterology 2003, 124:A48.CrossRefGoogle Scholar
  16. 16.
    Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187–1193.PubMedCrossRefGoogle Scholar
  17. 17.
    Braun J, Brandt J, Listing J, et al.: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003, 48:2224–2233.PubMedCrossRefGoogle Scholar
  18. 18.
    Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346:1349–1356.PubMedCrossRefGoogle Scholar
  19. 19.
    Brandt J, Khariouzov A, Listing J, et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003, 48:1667–1675.PubMedCrossRefGoogle Scholar
  20. 20.
    Davis JC Jr, Van Der Heijde D, Braun J, et al., and the Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48:3230–3236.PubMedCrossRefGoogle Scholar
  21. 21.
    Maksymowych WP, Inman RD, Gladman D, et al., and the Spondyloarthritis Research Consortium of Canada (SPARCC): Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003, 30:1356–1363. Consensus statement from a national rheumatologic society outlining indications for anti-TNF therapy in spondyloarthropathy.PubMedGoogle Scholar
  22. 22.
    Palm O, Moum B, Jahnsen J, Gran JT: The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population-based study (the IBSEN study). Rheumatology 2001, 40:1256–1261.PubMedCrossRefGoogle Scholar
  23. 23.
    Orchard TR, Wordsworth BP, Jewell DP: Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387–391.PubMedCrossRefGoogle Scholar
  24. 24.
    Orchard TR, Thiyagaraja S, Welsh KI, et al.: Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000, 118:274–278.PubMedCrossRefGoogle Scholar
  25. 25.
    Balbir-Gurman A, Schapira D, Nahir M: Arthritis related to ileal pouchitis following total proctocolectomy for ulcerative colitis. Semin Arthritis Rheum 2001, 30:242–248.PubMedCrossRefGoogle Scholar
  26. 26.
    Reinisch W, Miehsler W, Dejaco C, et al.: An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther 2003, 17:1371–1380. An uncontrolled study suggesting that rofecoxib does not significantly increase the risk of disease exacerbation in IBD.PubMedCrossRefGoogle Scholar
  27. 27.
    Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ: Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002, 97:910–914.PubMedCrossRefGoogle Scholar
  28. 28.
    Menachem Y, Gotsman I: Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 2004, 6:88–90.PubMedGoogle Scholar
  29. 29.
    Newman B, Cescon D, Domenchini A, Siminovitch KA:CD2BP1 and CARD15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease. J Invest Dermatol 2004, 122:1054–1056.PubMedCrossRefGoogle Scholar
  30. 30.
    Vidal D, Alomar A: Successful treatment of periostomal pyoderma gangrenosum using topical tacrolimus. Br J Dermatol 2004, 150:387–388.PubMedCrossRefGoogle Scholar
  31. 31.
    Ljung T, Staun M, Grove O, et al.: Pyoderma gangrenosum associated with Crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002, 37:1108–1110.PubMedCrossRefGoogle Scholar
  32. 32.
    Kugathasan S, Miranda A, Nocton J, et al.: Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003, 37:150–154.PubMedCrossRefGoogle Scholar
  33. 33.
    Regueiro M, Valentine J, Plevy S, et al.: Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003, 98:1821–1826. Case series demonstrating the effectiveness of infliximab in refractory pyoderma gangrenosum.PubMedCrossRefGoogle Scholar
  34. 34.
    Mintz R, Feller ER, Bahr RL, Shah SA: Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:135–139.PubMedCrossRefGoogle Scholar
  35. 35.
    Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al.:Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003, 30:1277–1279.PubMedGoogle Scholar
  36. 36.
    Kaplan-Messas A, Barkana Y, Avni I, Neumann R: Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocular Immunol Inflamm 2003, 11:131–139.CrossRefGoogle Scholar
  37. 37.
    Baltatzis S, Tufail F, Yu EN, et al.: Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003, 110:1061–1065.PubMedCrossRefGoogle Scholar
  38. 38.
    Lau CH, Comer M, Lightman S: Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol 2003, 31:487–491.CrossRefGoogle Scholar
  39. 39.
    Joseph A, Raj D, Dua HS, et al.: Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003, 110:1449–1453.PubMedCrossRefGoogle Scholar
  40. 40.
    Murphy CC, Ayliffe WH, Booth A, et al.: Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004, 111:352–356.PubMedCrossRefGoogle Scholar
  41. 41.
    Reiff A:Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum 2003, 48:2079–2080.PubMedCrossRefGoogle Scholar
  42. 42.
    Foster CS, Tufail F, Waheed NK, et al.: Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121:437–440.PubMedCrossRefGoogle Scholar
  43. 43.
    Murphy CC, Greiner K, Plskova J, et al.: Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 2004, 122:845–851.PubMedCrossRefGoogle Scholar
  44. 44.
    Nussenblatt RB, Thompson DJ, Li Z, et al.: Humanized antiinterleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003, 21:283–293.PubMedCrossRefGoogle Scholar
  45. 45.
    Papaliodis GN, Chu D, Foster CS: Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110:786–789.PubMedCrossRefGoogle Scholar
  46. 46.
    Bambha K, Kim WR, Talwalkar J, et al.: Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364–1369. First population-based study of the incidence and clinical features of PSC from a region in the United States.PubMedCrossRefGoogle Scholar
  47. 47.
    Florin TH, Pandeya N, Radford-Smith GL: Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut 2004, 53:973–979.PubMedCrossRefGoogle Scholar
  48. 48.
    Perdigoto R, Wiesner RH, LaRusso NF, Dozois R: Inflammatory bowel disease associated with primary sclerosing cholangitis: incidence, severity and relationship to liver disease [abstract]. Gastroenterology 1991, 100:A238.Google Scholar
  49. 49.
    Harewood GC, Loftus EV, Tremaine WJ, Sandborn WJ: ‘PSCIBD’: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis [abstract]. Gastroenterology 1999, 116:A732.CrossRefGoogle Scholar
  50. 50.
    Loftus EV, Harewood GC, Loftus CG, et al.: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2004, in press. Comparison of the colonoscopic features of PSC-associated IBD with UC, demonstrating that rectal sparing and backwash ileitis are more common in PSC-IBD.Google Scholar
  51. 51.
    Boberg KM, Egeland T, Schrumpf E: Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 2003, 38:991–995.PubMedCrossRefGoogle Scholar
  52. 52.
    Epstein MP, Kaplan MM: A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004, 49:1–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Haagsma EB, Van Den Berg AP, Kleibeuker JH, et al.:Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment Pharmacol Ther 2003, 18:33–44.PubMedCrossRefGoogle Scholar
  54. 54.
    Vera A, Gunson BK, Ussatoff V, et al.: Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003, 75:1983–1988.PubMedCrossRefGoogle Scholar
  55. 55.
    Bernstein CN, Leslie WD, Leboff MS: AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795–841. Comprehensive review of IBD-associated osteoporosis that served as a basis for AGA practice guidelines.PubMedCrossRefGoogle Scholar
  56. 56.
    American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:791–794.CrossRefGoogle Scholar
  57. 57.
    Bernstein CN, Katz S: Osteoporosis and Inflammatory Bowel Disease: A Guide to Diagnosis and Management for the Gastroenterologist. Arlington, VA: American College of Gastroenterology; 2002.Google Scholar
  58. 58.
    Jahnsen J, Falch JA, Mowinckel P, Aadland E: Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand J Gastroenterol 2004, 39:145–153.PubMedCrossRefGoogle Scholar
  59. 59.
    Hanley DA, Brown JP, Tenenhouse A, et al., and the CanadianMulticentre Osteoporosis Study Research Group: Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 2003, 18:784–790.PubMedCrossRefGoogle Scholar
  60. 60.
    de Jong DJ, Mannaerts L, van Rossum LG, et al.: Longitudinal study of bone mineral density in patients with Crohn’s disease. Dig Dis Sci 2003, 48:1355–1359.CrossRefGoogle Scholar
  61. 61.
    Bernstein CN, Leslie WD, Taback SP: Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol 2003, 98:1094–1100.PubMedCrossRefGoogle Scholar
  62. 62.
    Bernstein CN, Bector S, Leslie WD: Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol 2003, 98:2468–2473.PubMedCrossRefGoogle Scholar
  63. 63.
    Siffledeen JS, Siminoski K, Steinhart H, et al.: The frequency of vitamin D deficiency in adults with Crohn’s disease. Can J Gastroenterol 2003, 17:473–478.PubMedGoogle Scholar
  64. 64.
    Bernstein CN, Blanchard JF, Leslie W, et al.: The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 2000, 133:795–799.PubMedGoogle Scholar
  65. 65.
    Vestergaard P, Mosekilde L: Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002, 156:1–10.PubMedCrossRefGoogle Scholar
  66. 66.
    Loftus EV Jr, Crowson CS, Sandborn WJ, et al.: Long-term fracture risk in patients with Crohn’s disease: a populationbased study in Olmsted County, Minnesota. Gastroenterology 2002, 123:468–475.PubMedCrossRefGoogle Scholar
  67. 67.
    Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al.: Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2003, 1:465–473.PubMedCrossRefGoogle Scholar
  68. 68.
    van Staa TP, Cooper C, Brusse LS, et al.: Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003, 125:1591–1597. Large case-control study from the GPRD demonstrating a relationship between hip and vertebral fractures and IBD.PubMedCrossRefGoogle Scholar
  69. 69.
    Card T, West J, Hubbard R, Logan RF: Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 2004, 53:251–255. Large matched cohort study, also from the GPRD, demonstrating an increased risk of hip fracture in Crohn’s disease and UC. This study also suggests that corticosteroid use further increased the risk of fracture.PubMedCrossRefGoogle Scholar
  70. 70.
    Bernstein CN, Blanchard JF, Metge C, Yogendran M: The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003, 98:1797–1801.PubMedCrossRefGoogle Scholar
  71. 71.
    Bartram SA, Peaston RT, Rawlings DJ, et al.: A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn’s disease. Aliment Pharmacol Ther 2003, 18:1121–1127.PubMedCrossRefGoogle Scholar
  72. 72.
    von Tirpitz C, Klaus J, Steinkamp M, et al.: Therapy of osteoporosis in patients with Crohn’s disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003, 17:807–816.CrossRefGoogle Scholar
  73. 73.
    Papa A, Danese S, Grillo A, et al.: Review article: Inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003, 98:1247–1251.PubMedCrossRefGoogle Scholar
  74. 74.
    Bernstein CN, Blanchard JF, Houston DS, Wajda A: The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001, 85:430–434.PubMedGoogle Scholar
  75. 75.
    Miehsler W, Reinisch W, Valic E, et al.: Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004, 53:542–548. IBD appears to be a risk factor for thromboembolism, whereas rheumatoid arthritis and celiac disease do not.PubMedCrossRefGoogle Scholar
  76. 76.
    Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ: Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol 2004, 99:97–101.PubMedCrossRefGoogle Scholar
  77. 77.
    Papa A, Danese S, Piccirillo N, et al.: Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events. Hepatogastroenterology 2003, 50:132–135.PubMedGoogle Scholar
  78. 78.
    Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526–535.PubMedCrossRefGoogle Scholar
  79. 79.
    Soetikno RM, Lin OS, Heidenreich PA, et al.: Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48–54.PubMedCrossRefGoogle Scholar
  80. 80.
    Lakatos L, Mester G, Erdelyi Z, et al.: Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977–2001. World J Gastroenterol 2004, 10:404–409.PubMedGoogle Scholar
  81. 81.
    Langholz E, Munkholm P, Davidsen M, Binder V: Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992, 103:1444–1451.PubMedGoogle Scholar
  82. 82.
    Munkholm P, Langholz E, Davidsen M, Binder V: Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 1993, 105:1716–1723.PubMedGoogle Scholar
  83. 83.
    Jess T, Winther KV, Munkholm P, et al.: Intestinal and extraintestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther 2004, 19:287–293. Population-based study from Copenhagen County, Denmark demonstrating an elevated risk of small bowel cancer, but not colorectal cancer, in an incidence cohort of Crohn’s disease.PubMedCrossRefGoogle Scholar
  84. 84.
    Winther KV, Jess T, Langholz E, et al.: Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004, in press.Google Scholar
  85. 85.
    Chen R, Rabinovitch PS, Crispin DA, et al.: DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancerfree. Am J Pathol 2003, 162:665–672.PubMedGoogle Scholar
  86. 86.
    Lashner BA, Bauer WM, Rybicki LA, Goldblum JR: Abnormal p53 immunohistochemistry is associated with an increased colorectal cancer-related mortality in patients with ulcerative colitis. Am J Gastroenterol 2003, 98:1423–1427.PubMedGoogle Scholar
  87. 87.
    Kiesslich R, Fritsch J, Holtmann M, et al.: Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003, 124:880–888. In a randomized prospective study, this promising technique detected three times as many dysplastic lesions as did conventional surveillance colonoscopy.PubMedCrossRefGoogle Scholar
  88. 88.
    Hurlstone DP, McAlindon ME, Sanders DS, et al.: Further validation of high-magnification chromoscopic-colonoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2004, 126:376–378.PubMedCrossRefGoogle Scholar
  89. 89.
    Ullman T, Croog V, Harpaz N, et al.: Progression of flat lowgrade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003, 125:1311–1319. The actuarial progression rate of low-grade dysplasia to either highgrade dysplasia or cancer was over 50% after 5 years.PubMedCrossRefGoogle Scholar
  90. 90.
    Ullman TA, Loftus EV Jr, Kakar S, et al.: The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002, 97:922–927.PubMedCrossRefGoogle Scholar
  91. 91.
    Rubin DT, Djordjevic A, Huo D, et al.: Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis [abstract]. Gastroenterology 2003, 124:A36.CrossRefGoogle Scholar
  92. 92.
    van Staa TP, Card T, Leufkens HGM, Logan RF: Prior aminosalicylate use and the development of colorectal cancer in inflammatory bowel disease (IBD): a large British epidemiological study [abstract]. Am J Gastroenterol 2003, 98:S244-S245. In this nested case-control study from the GPRD, regular users of 5-aminosalicylate agents were approximately 30% to 40% less likely to develop colorectal cancer than were irregular users.CrossRefGoogle Scholar
  93. 93.
    Bernstein CN, Blanchard JF, Metge C, Yogendran M: Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003, 98:2784–2788.PubMedCrossRefGoogle Scholar
  94. 94.
    Rutter M, Saunders B, Wilkinson K, et al.: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451–459.PubMedCrossRefGoogle Scholar
  95. 95.
    Velayos FS, Walsh JME, Terdiman JP: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk in ulcerative colitis: a meta-analysis [abstract]. Gastroenterology 2004, 126:A20. Meta-analysis of the observational studies on 5-aminosalicylate and colorectal neoplasia. Pooling of the data suggested a cancer risk reduction of 75%.Google Scholar
  96. 96.
    Pardi DS, Loftus EV Jr, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889–893. PSC-IBD patients who received UCDA in a randomized trial were 74% less likely than those receiving placebo to develop colorectal dysplasia or cancer.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Edward V. LoftusJr
    • 1
  1. 1.Division of Gastroenterology and HepatologyMayo Clinic College of MedicineRochesterUSA

Personalised recommendations